Phospho-LATS1/LATS2 (Thr1079/1041) Antibody

What is the Phospho-LATS1/LATS2 (Thr1079/1041) Antibody?

Phospho-LATS1/LATS2 (Thr1079/1041) antibody is a rabbit polyclonal antibody that specifically detects LATS1/2 proteins only when phosphorylated at threonine 1079 (for LATS1) or threonine 1041 (for LATS2). This antibody is derived from a peptide sequence around the phosphorylation site with the amino acid sequence E-F-T(p)-F-R from human LATS1/2. It is typically available in liquid form at a concentration of 1 mg/mL in PBS buffer with 50% glycerol and 0.02% sodium azide at pH 7.4. The antibody has been validated for immunohistochemistry applications in paraffin-embedded samples and can detect these phosphorylated proteins in both human and mouse samples .

Unlike antibodies that detect total LATS1/2 protein, this phospho-specific antibody allows researchers to specifically monitor the activation status of these kinases, making it valuable for studying regulatory mechanisms in the Hippo pathway.

What is the biological significance of Thr1079/1041 phosphorylation in LATS1/2?

Phosphorylation at the hydrophobic motif (HM) sites Thr1079 (LATS1) and Thr1041 (LATS2) represents a critical regulatory step in LATS1/2 activation. These sites are targeted by upstream kinases including MST1/2, MAP4K family, and TAO kinases in the canonical Hippo pathway. The phosphorylation of these threonine residues serves as a molecular switch that promotes autophosphorylation of LATS1/2 at their activation loop (AL) sites (Ser909 for LATS1 and Ser872 for LATS2) .

This sequential phosphorylation mechanism is essential for full activation of LATS1/2 kinases, which subsequently phosphorylate and inhibit YAP/TAZ transcriptional co-activators. The ability to monitor Thr1079/1041 phosphorylation provides direct insight into the initial activation step of LATS1/2 and helps researchers understand upstream regulatory events in the Hippo pathway.

How does LATS1/2 activation regulate downstream signaling events?

Once LATS1/2 becomes phosphorylated at the hydrophobic motif (Thr1079/1041) and subsequently at the activation loop (Ser909/872), these fully activated kinases phosphorylate multiple sites on YAP and TAZ. The phosphorylation of YAP at Ser127 and TAZ at Ser89 creates binding sites for 14-3-3 proteins, leading to cytoplasmic sequestration and prevention of their nuclear translocation. Additionally, phosphorylation at YAP Ser381 and TAZ Ser311 primes these proteins for subsequent phosphorylation by casein kinase 1, leading to their ubiquitination and proteasomal degradation .

These regulatory mechanisms prevent YAP/TAZ from acting as transcriptional co-activators in the nucleus, thereby inhibiting the expression of genes involved in cell proliferation and anti-apoptosis. The dysregulation of this signaling axis is commonly observed in various cancers, highlighting the significance of monitoring LATS1/2 phosphorylation status in oncological research.

What experimental applications is the Phospho-LATS1/LATS2 (Thr1079/1041) antibody suitable for?

The Phospho-LATS1/LATS2 (Thr1079/1041) antibody has been validated primarily for immunohistochemistry (IHC) on paraffin-embedded tissue sections. Human brain tissue is suggested as a positive control for IHC applications . While not explicitly validated in the provided information, similar phospho-specific antibodies are commonly used in:

• Western blotting: For quantitative assessment of phosphorylation levels

• Immunoprecipitation: To isolate phosphorylated LATS1/2 complexes

• Immunofluorescence: For subcellular localization studies

When adapting this antibody for applications beyond IHC, researchers should perform proper validation studies, including phosphatase treatment controls and comparison with total LATS1/2 antibodies to confirm specificity. The antibody's reactivity with human and mouse samples makes it suitable for comparative studies between these species, though cross-reactivity with other organisms should be empirically determined.

What are the optimal sample preparation techniques for detecting phosphorylated LATS1/2?

Detecting phosphorylated proteins requires careful consideration of sample preparation to preserve phosphorylation status:

• Sample collection: Rapidly harvest and process samples, as phosphorylation status can change quickly after tissue collection or cell lysis.

• Lysis buffer composition: Include phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate) in all buffers to prevent dephosphorylation during sample processing.

• Fixation for IHC:

  • For paraffin sections: 10% neutral buffered formalin is recommended

  • Fixation time should be optimized to balance antigen preservation and tissue morphology

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) is typically effective for phospho-epitopes.

• Blocking: Use bovine serum albumin (BSA) rather than milk for blocking and antibody dilution, as milk contains phospho-proteins that may increase background.

For human brain tissue specifically recommended as a positive control , ensure rapid post-mortem collection and fixation to preserve phosphorylation status, as neural tissues are particularly vulnerable to rapid enzymatic changes.

How do angiomotins influence LATS1/2 phosphorylation at Thr1079/1041 sites?

Angiomotins (AMOT, AMOTL1, and AMOTL2) play a significant role in regulating LATS1/2 activity through a complex feedback mechanism. Research indicates that all three angiomotin family members promote LATS2 hydrophobic motif (HM) phosphorylation at Thr1041 . This relationship involves several intriguing molecular mechanisms:

• Binding preference for activated LATS: Angiomotins preferentially bind to active forms of LATS2 rather than inactive forms. Experiments have shown that wild-type LATS2 exhibits stronger binding to AMOT and AMOTL2 compared to LATS2 mutants with both activating phosphorylation sites mutated to alanine .

• Bidirectional regulation: LATS2 phosphorylates AMOT at Ser175, and this phosphorylation enhances AMOT-LATS2 binding. A phosphomimetic version of AMOT (AMOT-175E) shows increased binding to LATS2 and promotes LATS2 activation compared to a non-phosphorylatable form (AMOT-175A) .

• Dependency on MST1/2 activity: The AMOT-LATS2 interaction is impaired in MST1/2-knockout cells, suggesting that MST1/2-mediated phosphorylation of LATS2 is required for optimal angiomotin binding. Interestingly, expression of a phosphomimetic LATS2 (LATS2-1041E) rescues the defect in AMOT-LATS2 interaction in MST1/2-deleted cells .

This suggests a positive feedback loop where initial MST1/2-mediated phosphorylation of LATS1/2 enhances angiomotin binding, which further promotes LATS1/2 activation, amplifying the signal. This mechanism provides insight into how sustained LATS1/2 activation might be achieved physiologically.

What is the functional relationship between the two phosphorylation sites (Thr1079/1041 and Ser909/872) in LATS1/2 activation?

The full activation of LATS1/2 involves a coordinated two-step phosphorylation process:

• Initial HM phosphorylation (Thr1079/1041): Upstream kinases like MST1/2, MAP4K family, and TAO kinases phosphorylate the hydrophobic motif sites (Thr1079 in LATS1 or Thr1041 in LATS2) .

• Subsequent AL autophosphorylation (Ser909/872): Once the HM site is phosphorylated, LATS1/2 undergoes autophosphorylation at its activation loop (Ser909 in LATS1 or Ser872 in LATS2) .

This sequential phosphorylation represents a molecular mechanism for ensuring controlled activation of LATS1/2. The HM phosphorylation serves as a regulatory checkpoint that must be passed before the kinase can become fully active through AL phosphorylation. This two-step process provides opportunities for multiple layers of regulation and signal integration.

The table below summarizes the key phosphorylation sites and their functions:

Experimentally, researchers can use phospho-specific antibodies targeting either site to determine where in the activation sequence a particular stimulus or inhibitor might be acting, providing mechanistic insights into pathway regulation.

How does the MST-MOB1-LATS complex formation influence LATS1/2 phosphorylation?

The formation of the MST-MOB1-LATS complex represents a critical step in the canonical Hippo pathway activation and LATS1/2 phosphorylation. This process follows a specific sequence:

• Complex assembly at the membrane: LATS1/2 are recruited to MST-MOB1 at the cell membrane by Neurofibromatosis 2 (NF2, also known as Merlin) .

• MST1/2-mediated phosphorylation: Within this complex, MST1/2 phosphorylate both MOB1 and the LATS1/2 hydrophobic motif (Thr1079 for LATS1 and Thr1041 for LATS2) .

• Complex dissociation: Following phosphorylation, the phosphorylated MOB1-LATS1/2 complex detaches from MST1/2 .

• LATS1/2 autophosphorylation: The released complex allows LATS1/2 to undergo autophosphorylation at its activation loop (Ser909 for LATS1 and Ser872 for LATS2), becoming fully active .

This dynamic assembly and disassembly of the signaling complex ensures proper spatial and temporal control of LATS1/2 activation. The membrane localization of this activation process is particularly important, as it creates a distinct compartment for initiating Hippo pathway signaling in response to various upstream cues such as cell-cell contact, mechanical forces, and soluble factors.

Methodologically, studying this complex formation requires techniques that can capture transient protein-protein interactions, such as proximity ligation assays, FRET-based approaches, or co-immunoprecipitation with crosslinking.

What experimental approaches can distinguish between LATS1 and LATS2 phosphorylation?

Despite their similarity, distinguishing between LATS1 and LATS2 phosphorylation is important for understanding their potentially distinct functions. Here are methodological approaches to differentiate them:

• Isoform-specific knockdown/knockout: Using siRNA, shRNA, or CRISPR-Cas9 to selectively deplete either LATS1 or LATS2, followed by detection with the Phospho-LATS1/LATS2 (Thr1079/1041) antibody to determine the contribution of each isoform to the observed signal.

• Isoform-specific immunoprecipitation: Using antibodies targeting unique regions of LATS1 or LATS2 for immunoprecipitation, followed by immunoblotting with the phospho-specific antibody.

• Mass spectrometry-based approaches:

  • Phosphopeptide enrichment followed by LC-MS/MS can identify isoform-specific phosphopeptides

  • Selected reaction monitoring (SRM) or parallel reaction monitoring (PRM) can quantify specific phosphopeptides from each isoform

• Genetic models: Using cell lines or animal models expressing only one LATS isoform (e.g., LATS1-/- or LATS2-/- backgrounds) to study isoform-specific phosphorylation.

• Recombinant protein studies: In vitro kinase assays with purified LATS1 or LATS2 to determine phosphorylation patterns and kinetics.

How is LATS1/2 phosphorylation dysregulated in cancer and what methodologies exist to study this?

The Hippo pathway is frequently dysregulated in cancer, contributing to tumor growth, development, and metastasis . Interestingly, mutations in core components of the Hippo pathway, including LATS1/2, are relatively rare in cancer patients, suggesting that non-mutational mechanisms might suppress this pathway . Several methodological approaches can be employed to study LATS1/2 phosphorylation dysregulation in cancer:

• Comparative tissue analysis:

  • Paired tumor/normal tissue immunohistochemistry using Phospho-LATS1/LATS2 (Thr1079/1041) antibody

  • Tissue microarray (TMA) analysis across multiple cancer types and stages

• Correlation with clinical parameters:

  • Association of LATS1/2 phosphorylation status with patient survival

  • Multivariate analysis with other prognostic factors

• Mechanistic studies:

  • Analysis of upstream regulators (MST1/2, MAP4Ks) and downstream targets (YAP/TAZ)

  • Evaluation of pathway cross-talk with other oncogenic pathways

• Epigenetic regulation:

  • Promoter methylation analysis of LATS1/2 genes

  • Histone modification profiling at LATS1/2 loci

• Post-translational regulation:

  • Analysis of phosphatases targeting LATS1/2

  • Investigation of other modifications like ubiquitination, SUMOylation, or O-GlcNAcylation that might interfere with phosphorylation

When using Phospho-LATS1/LATS2 (Thr1079/1041) antibody in cancer research, it's crucial to consider the heterogeneity of tumor tissues and include appropriate controls. Human brain tissue has been suggested as a positive control for IHC applications with this antibody , which may serve as a reference standard when examining various cancer samples.

What are common technical challenges when using Phospho-LATS1/LATS2 (Thr1079/1041) antibody in immunohistochemistry?

Researchers commonly encounter several challenges when using phospho-specific antibodies in immunohistochemistry (IHC), especially for targets like LATS1/2:

• Preservation of phospho-epitopes:

  • Challenge: Phosphorylation status can be rapidly lost during tissue harvesting, fixation, and processing due to endogenous phosphatase activity.

  • Solution: Immediate fixation of tissues (within minutes of collection), inclusion of phosphatase inhibitors in all buffers, and optimization of fixation time.

• Antigen retrieval optimization:

  • Challenge: Overfixation can mask epitopes, while insufficient antigen retrieval may prevent antibody access.

  • Solution: Systematic testing of different antigen retrieval methods (heat-induced vs. enzymatic), buffers (citrate pH 6.0 vs. EDTA pH 9.0), and times.

• Specificity verification:

  • Challenge: Ensuring the antibody detects only phosphorylated LATS1/2 and not unphosphorylated forms.

  • Solution: Include controls such as lambda phosphatase-treated sections, tissues from LATS1/2 knockout models, and peptide competition assays.

• Signal amplification without background:

  • Challenge: Phospho-specific epitopes may be present at low abundance.

  • Solution: Test various detection systems (ABC, polymer-based) and optimize signal amplification techniques while monitoring background signals.

For the Phospho-LATS1/LATS2 (Thr1079/1041) antibody specifically, human brain tissue has been recommended as a positive control . This suggests that neural tissues may have detectable levels of phosphorylated LATS1/2, providing a benchmark for optimization.

How can researchers optimize western blot protocols for detecting phosphorylated LATS1/2?

Western blotting for phosphorylated LATS1/2 requires special considerations to maintain phosphorylation status and achieve optimal sensitivity:

• Sample preparation:

  • Harvest cells rapidly and lyse in cold buffer containing phosphatase inhibitors (10 mM NaF, 1 mM Na₃VO₄, 10 mM β-glycerophosphate)

  • Add protease inhibitors to prevent degradation of LATS1/2 proteins

  • Maintain samples at 4°C throughout processing

• Gel electrophoresis:

  • Use lower percentage gels (6-8%) for better resolution of high molecular weight LATS1/2 proteins

  • LATS1 is approximately 140 kDa and LATS2 is approximately 120 kDa

  • Consider using gradient gels for simultaneous detection of LATS1/2 and lower molecular weight markers

• Transfer optimization:

  • Longer transfer times or semi-dry systems for efficient transfer of large proteins

  • Methanol-free transfer buffer may improve transfer of large proteins

• Blocking and antibody incubation:

  • Use BSA instead of milk for blocking (milk contains phospho-proteins)

  • Optimize primary antibody dilution (typically starting at 1:1000)

  • Consider overnight incubation at 4°C to maximize sensitivity

• Detection system:

  • Enhanced chemiluminescence (ECL) systems with extended dynamic range

  • Consider fluorescent secondary antibodies for more quantitative analysis

• Controls:

  • Positive control: Lysate from cells treated with Okadaic acid (phosphatase inhibitor)

  • Negative control: Lambda phosphatase-treated lysate

  • Loading control: Total LATS1/2 on stripped membrane or parallel blot

• Multiplexing strategy:

  • Sequential blotting order: phospho-LATS1/2 first, then strip and reprobe for total LATS1/2

  • Alternatively, use different host species antibodies for simultaneous detection on dual-channel imaging systems

What controls should be included when studying LATS1/2 phosphorylation?

Robust experimental design for studying LATS1/2 phosphorylation should include multiple controls to ensure validity and interpretability of results:

• Positive controls:

  • Cells treated with phosphatase inhibitors (e.g., okadaic acid, calyculin A)

  • Tissues known to express high levels of phosphorylated LATS1/2 (e.g., human brain tissue)

  • Cells with activated Hippo pathway (e.g., high density culture, serum starvation)

• Negative controls:

  • Lambda phosphatase treatment of samples to remove phosphorylation

  • LATS1/2 knockdown or knockout samples

  • Samples treated with MST1/2 inhibitors to prevent LATS1/2 phosphorylation

• Specificity controls:

  • Peptide competition assays using phosphorylated and non-phosphorylated peptides

  • Parallel detection with other phospho-LATS1/2 antibodies (e.g., Phospho-LATS1/LATS2 Ser909/Ser872)

  • Immunoprecipitation followed by mass spectrometry to confirm specific detection

• Pathway controls:

  • Monitoring downstream targets (e.g., phospho-YAP) to confirm functional significance

  • Upstream activators (e.g., MST1/2 phosphorylation) to validate pathway integrity

  • Parallel analysis with total LATS1/2 antibodies to normalize phosphorylation signals

• Technical controls:

  • Secondary antibody-only controls to assess non-specific binding

  • Isotype controls to evaluate background

  • Consistent positive reference samples across experiments for inter-experimental comparison

What are the most effective methods for studying temporal dynamics of LATS1/2 phosphorylation?

Understanding the temporal dynamics of LATS1/2 phosphorylation is crucial for elucidating signaling kinetics and regulatory mechanisms. Several methodological approaches are particularly suited for this purpose:

• Time-course experiments:

  • Stimulate cells with pathway activators and collect samples at multiple timepoints

  • Use synchronized cell populations to examine cell cycle-dependent phosphorylation

  • Compare kinetics of HM (Thr1079/1041) versus AL (Ser909/872) phosphorylation

• Live-cell imaging approaches:

  • FRET-based biosensors for LATS1/2 conformational changes upon phosphorylation

  • Fluorescently-tagged LATS1/2 to monitor subcellular localization dynamics

  • Split luciferase complementation assays to monitor LATS1/2 interaction with partners

• Pulse-chase analyses:

  • Metabolic labeling with ³²P-orthophosphate followed by immunoprecipitation

  • SILAC-based phosphoproteomic analysis at different timepoints

  • Targeted mass spectrometry with heavy-labeled phosphopeptide standards

• Single-cell analytical methods:

  • Flow cytometry with phospho-specific antibodies

  • Mass cytometry (CyTOF) for multi-parameter analysis

  • Single-cell western blotting for population heterogeneity assessment

• Computational approaches:

  • Mathematical modeling of phosphorylation/dephosphorylation kinetics

  • Integration of multiple phosphorylation sites into pathway models

  • Machine learning-based analysis of complex temporal patterns

For the Phospho-LATS1/LATS2 (Thr1079/1041) antibody, designing time-course experiments that capture both rapid events (seconds to minutes) and sustained responses (hours to days) will provide comprehensive understanding of how this phosphorylation is regulated under different physiological and pathological conditions.

How can researchers distinguish between direct and indirect effects on LATS1/2 phosphorylation?

Distinguishing between direct and indirect modulators of LATS1/2 phosphorylation is critical for accurate pathway mapping. Several experimental approaches can help make this distinction:

• In vitro kinase assays:

  • Purified candidate upstream kinases with recombinant LATS1/2 as substrate

  • ATP analog-sensitive kinase mutants combined with modified ATP analogs

  • Comparison of reaction kinetics with and without scaffold proteins

• Rapid perturbation strategies:

  • Acute chemical inhibition (e.g., using small molecule inhibitors)

  • Optogenetic activation/inhibition of candidate regulators

  • Rapid protein degradation systems (e.g., auxin-inducible degron)

• Proximity-based approaches:

  • BioID or TurboID proximity labeling to identify proteins in close proximity to LATS1/2

  • APEX2-based proximity labeling for temporal resolution

  • FRET/BRET between candidate regulators and LATS1/2

• Reconstitution systems:

  • Cell-free biochemical systems with purified components

  • Heterologous expression in systems lacking endogenous Hippo pathway

  • Synthetic biology approaches with engineered signaling components

• Sequential perturbation analysis:

  • Kinetic analysis comparing phosphorylation of different sites

  • Inhibitor studies with multiple pathway components

  • Genetic epistasis experiments with multiple knockdowns/knockouts

When working with the Phospho-LATS1/LATS2 (Thr1079/1041) antibody, combining these approaches with phospho-specific detection will provide a more complete understanding of the direct versus indirect regulators controlling this critical phosphorylation event.

How do Phospho-LATS1/LATS2 (Thr1079/1041) and Phospho-LATS1/LATS2 (Ser909/Ser872) antibodies complement each other in research?

The complementary use of antibodies targeting different phosphorylation sites on LATS1/2 provides powerful insights into activation mechanisms and signaling dynamics:

Using these antibodies in combination allows researchers to:

• Dissect activation mechanisms: Determine whether a particular stimulus affects upstream kinase activity (detected by Thr1079/1041 phosphorylation) or LATS1/2 autophosphorylation capacity (detected by Ser909/872 phosphorylation).

• Identify signaling bottlenecks: Conditions where Thr1079/1041 phosphorylation increases without corresponding Ser909/872 phosphorylation may indicate inhibition at the autophosphorylation step.

• Temporal resolution: Track the sequence and timing of the two-step activation process in response to stimuli.

• Spatial analysis: Examine whether these phosphorylation events occur in different subcellular compartments, potentially revealing compartmentalized regulation.

The comparative use of these phospho-specific antibodies enhances the depth of mechanistic insights obtainable in Hippo pathway research and provides internal validation for activation status assessment.

What are the key differences in experimental design for studying LATS1/2 HM versus AL phosphorylation?

Studying hydrophobic motif (HM) phosphorylation (Thr1079/1041) versus activation loop (AL) phosphorylation (Ser909/872) requires tailored experimental approaches due to their distinct regulatory mechanisms:

For HM phosphorylation studies using the Phospho-LATS1/LATS2 (Thr1079/1041) antibody:

• Focus on manipulating upstream components like MST1/2 or angiomotins

• Monitor rapid changes following stimulus application

• Consider the role of scaffold proteins like MOB1 and NF2

• Examine subcellular localization, particularly membrane recruitment

For AL phosphorylation studies:

• Focus on conditions that affect LATS1/2 intrinsic activity

• Examine the relationship between HM and AL phosphorylation timing

• Consider ATP availability and metabolic state effects

• Investigate factors that might specifically block autophosphorylation

A comprehensive experimental design would examine both phosphorylation events in parallel to understand their interdependence and identify factors that might selectively affect one site versus the other.

How do angiomotins and NF2 differentially influence LATS1/2 phosphorylation?

Angiomotins (AMOT, AMOTL1, AMOTL2) and Neurofibromatosis type 2 (NF2/Merlin) both promote LATS1/2 phosphorylation but through distinct molecular mechanisms with important implications for experimental design and interpretation:

These differential mechanisms create important considerations for research:

• Positive feedback amplification: Angiomotins create a positive feedback loop where initial LATS1/2 activation (potentially through NF2-mediated mechanisms) enhances angiomotin-LATS1/2 binding, further amplifying LATS1/2 activation .

• Temporal dynamics: NF2 likely acts earlier in the activation sequence, facilitating initial complex formation, while angiomotins may contribute to signal amplification and maintenance.

• Context-specific regulation:

  • NF2 activation responds strongly to cell-cell contact

  • Angiomotins link LATS1/2 activity to mechanical forces and cytoskeletal tension

• Experimental design implications:

  • When studying angiomotin effects, consider the activation state of LATS1/2

  • For NF2 studies, examine membrane localization and complex formation

  • Both pathways may be differentially sensitive to specific upstream signals

Using the Phospho-LATS1/LATS2 (Thr1079/1041) antibody in combination with genetic or pharmacological manipulation of either angiomotins or NF2 can reveal their respective contributions to LATS1/2 activation in different biological contexts.

How does LATS1/2 phosphorylation pattern compare between in vitro cell culture and in vivo tissue samples?

The phosphorylation patterns of LATS1/2 can differ substantially between in vitro cell culture models and in vivo tissue samples, presenting important considerations for experimental design and data interpretation:

When using the Phospho-LATS1/LATS2 (Thr1079/1041) antibody across these different experimental systems:

• For in vitro studies:

  • Control cell density carefully

  • Consider the impact of culture substrate stiffness

  • Use rapid cell harvesting to preserve phosphorylation status

• For in vivo/tissue studies:

  • Human brain tissue has been suggested as a positive control

  • Minimize time between tissue collection and fixation

  • Consider perfusion fixation for animal models

  • Account for tissue heterogeneity in analysis

• Bridging the gap:

  • 3D organoid culture systems

  • Ex vivo tissue slice cultures

  • Patient-derived xenografts

Understanding these differences is crucial for translating findings between experimental systems and for designing studies that accurately capture physiologically relevant LATS1/2 phosphorylation patterns.

What is the relationship between LATS1/2 phosphorylation and its tumor suppressor function?

The relationship between LATS1/2 phosphorylation and its tumor suppressor function is multifaceted, with important implications for cancer research:

• Mechanistic basis of tumor suppression:

  • Phosphorylated LATS1/2 (at both Thr1079/1041 and Ser909/872) represents the active form

  • Active LATS1/2 phosphorylates YAP/TAZ, preventing their nuclear localization and transcriptional co-activator function

  • This inhibits expression of pro-proliferative and anti-apoptotic genes

  • LATS1/2 also has YAP/TAZ-independent tumor suppressor functions, including cell cycle regulation

• Dysregulation in cancer:

  • Reduced LATS1/2 phosphorylation is common in multiple cancer types

  • Mutations in LATS1/2 are relatively rare, suggesting non-mutational mechanisms of inactivation

  • Upstream regulators (MST1/2, NF2) are more frequently mutated

  • Epigenetic silencing of LATS1/2 genes occurs in some cancers

• Contextual considerations:

  • LATS1/2 may have tissue-specific functions

  • The protein encoded by the LATS1 gene localizes to the mitotic apparatus and complexes with CDC2 kinase in early mitosis

  • LATS1/2 phosphorylation status can vary across tumor regions

• Experimental evidence from knockout models:

  • LATS1 knockout mice develop soft-tissue sarcomas, ovarian stromal cell tumors, and show high sensitivity to carcinogenic treatments

  • These models confirm the tumor suppressor function suggested by biochemical and genetic data

Using the Phospho-LATS1/LATS2 (Thr1079/1041) antibody in cancer research can provide valuable insights into:

• Activation status of the Hippo pathway in different tumor types

• Correlation between LATS1/2 phosphorylation and clinical outcomes

• Efficacy of therapeutics aimed at restoring Hippo pathway activity

• Biomarker potential for patient stratification

What emerging technologies will advance our understanding of LATS1/2 phosphorylation dynamics?

Several cutting-edge technologies are poised to transform our understanding of LATS1/2 phosphorylation dynamics in the coming years:

• Advanced imaging technologies:

  • Super-resolution microscopy to visualize nanoscale LATS1/2 complexes

  • Lattice light-sheet microscopy for long-term 3D imaging with minimal phototoxicity

  • Expansion microscopy to physically enlarge subcellular structures for enhanced resolution

  • Correlative light and electron microscopy (CLEM) to link functional imaging with ultrastructural context

• Biosensor development:

  • Genetically encoded FRET-based sensors for real-time monitoring of LATS1/2 phosphorylation

  • Split fluorescent protein complementation systems for detecting LATS1/2 interactions

  • Synthetic biology approaches with engineered phosphorylation-dependent switches

• Single-cell technologies:

  • Single-cell phosphoproteomics to capture cell-to-cell variability

  • Spatial transcriptomics combined with phospho-protein detection

  • Multi-omics approaches integrating phosphorylation data with transcriptional outputs

• CRISPR-based screening and engineering:

  • CRISPR activation/interference screens for regulators of LATS1/2 phosphorylation

  • Base editing to introduce precise mutations at phosphorylation sites

  • CRISPR-mediated tagging of endogenous LATS1/2 for live monitoring

• Computational approaches:

  • Machine learning algorithms for predicting phosphorylation dynamics from multi-parameter datasets

  • Integrative mathematical modeling of the complete Hippo signaling network

  • Molecular dynamics simulations of phosphorylation-induced conformational changes

These technologies will complement traditional antibody-based approaches like those using the Phospho-LATS1/LATS2 (Thr1079/1041) antibody, providing multidimensional insights into the spatial, temporal, and contextual regulation of LATS1/2 phosphorylation in both physiological and pathological settings.

How might targeting LATS1/2 phosphorylation be leveraged for therapeutic development?

The critical role of LATS1/2 phosphorylation in controlling the Hippo pathway offers several promising avenues for therapeutic intervention:

• Restoring LATS1/2 phosphorylation in cancer:

  • Small molecule activators of upstream kinases (MST1/2, MAP4Ks)

  • Inhibitors of phosphatases that dephosphorylate LATS1/2

  • Peptide mimetics that stabilize the active conformation of LATS1/2

  • Angiomotin-derived peptides to enhance LATS1/2 activation

• Inhibiting excessive LATS1/2 activity in regenerative medicine:

  • ATP-competitive inhibitors of LATS1/2 kinase domains

  • Allosteric inhibitors that prevent LATS1/2 phosphorylation

  • Disrupting protein-protein interactions required for LATS1/2 activation

• Combination therapies:

  • Pairing Hippo pathway modulators with conventional chemotherapeutics

  • Combining with immunotherapies to enhance anti-tumor immunity

  • Sequential treatment strategies targeting different nodes of the pathway

• Targeted delivery strategies:

  • Nanoparticle-based delivery of LATS1/2 modulators to specific tissues

  • Cell type-specific activation using antibody-drug conjugates

  • Conditionally active compounds responsive to tumor microenvironment

• Biomarker-driven approaches:

  • Using Phospho-LATS1/LATS2 (Thr1079/1041) antibody-based assays for patient stratification

  • Developing companion diagnostics to identify responders to Hippo pathway modulation

  • Monitoring treatment efficacy through liquid biopsy approaches

The development of these therapeutic strategies will require robust assays for LATS1/2 phosphorylation status, where antibodies like the Phospho-LATS1/LATS2 (Thr1079/1041) will play a crucial role in both research and clinical applications. The specificity of this antibody for the phosphorylated form makes it particularly valuable for assessing target engagement and efficacy of compounds designed to modulate LATS1/2 activity.

What are the emerging non-canonical functions of phosphorylated LATS1/2?

Beyond its canonical role in the Hippo pathway, phosphorylated LATS1/2 has emerging functions that represent exciting frontiers in research:

• Cell cycle regulation:

  • LATS1 localizes to the mitotic apparatus and complexes with CDC2 kinase in early mitosis

  • It is phosphorylated in a cell-cycle dependent manner, with late prophase phosphorylation persisting through metaphase

  • LATS1 acts as a negative regulator of CDC2/cyclin A through its N-terminal binding to CDC2

• DNA damage response:

  • Emerging evidence suggests phosphorylated LATS1/2 participates in DNA repair processes

  • Potential roles in cell cycle checkpoints following genotoxic stress

  • Interactions with p53 and other tumor suppressor networks

• Metabolic regulation:

  • Links between LATS1/2 phosphorylation status and cellular metabolism

  • Roles in mitochondrial function and energy homeostasis

  • Connection to nutrient sensing pathways

• Immune modulation:

  • Effects on inflammatory signaling

  • Influence on immune cell function and tumor microenvironment

  • Potential therapeutic implications in immuno-oncology

• Epigenetic regulation:

  • Emerging roles in chromatin remodeling

  • Direct and indirect effects on gene expression beyond YAP/TAZ regulation

  • Potential transgenerational implications

These non-canonical functions expand the significance of monitoring LATS1/2 phosphorylation using antibodies like the Phospho-LATS1/LATS2 (Thr1079/1041). Researchers investigating these emerging areas should consider multiple phosphorylation sites and their interdependence, as different functions may be regulated by distinct phosphorylation patterns or combinations.